{
    "xml": "<topic id=\"PHP5436\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/bevacizumab\" basename=\"bevacizumab\" title=\"BEVACIZUMAB\">\n<title>BEVACIZUMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1261\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/bevacizumab\">Bevacizumab</xref>\n</p>\n<data name=\"vtmid\">409405006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_872447286\" title=\"Monoclonal antibodies (antineoplastic)\">Monoclonal antibodies (antineoplastic)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP45485\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/bevacizumab\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>\n<b>Bevacizumab</b> is a monoclonal antibody that inhibits vascular endothelial growth factor.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45453\" outputclass=\"indicationsAndDose\" rev=\"1.16\" parent=\"/drugs/bevacizumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy</p>\n<p outputclass=\"therapeuticIndication\">First-line treatment of metastatic breast cancer in combination with paclitaxel when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate</p>\n<p outputclass=\"therapeuticIndication\">First-line treatment of metastatic breast cancer in combination with capecitabine when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate (patients who have received adjuvant taxane or anthracycline-containing regimens in the previous 12 months should not be treated with bevacizumab in combination with capecitabine)</p>\n<p outputclass=\"therapeuticIndication\">Advanced or metastatic renal cell carcinoma in combination with interferon alfa-2a</p>\n<p outputclass=\"therapeuticIndication\">First-line treatment of unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology (In combination with platinum-based chemotherapy)</p>\n<p outputclass=\"therapeuticIndication\">First-line treatment of advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with carboplatin and paclitaxel)</p>\n<p outputclass=\"therapeuticIndication\">First recurrence of platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have not been treated previously with bevacizumab or other drugs that target vascular endothelial growth factor (in combination with carboplatin and gemcitabine)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult local protocol).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45492\" outputclass=\"importantSafetyInformation\" rev=\"1.10\" parent=\"/drugs/bevacizumab\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">MHRA/CHM advice: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (January 2011)</p>\n<p>Treatment with bevacizumab or sunitinib may be a risk factor for the development of osteonecrosis of the jaw.</p>\n<p>Patients treated with bevacizumab or sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.</p>\n<p>Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.</p>\n<p>If possible, invasive dental procedures should be avoided in patients treated with bevacizumab or sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45524\" outputclass=\"cautions\" rev=\"1.18\" parent=\"/drugs/bevacizumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Elective surgery (withhold treatment and avoid for at least 28 days after major surgery or until wound fully healed)</ph>; <ph outputclass=\"caution\">history of arterial thromboembolism</ph>; <ph outputclass=\"caution\">history of cardiovascular disease (increased risk of cardiovascular events, especially in the elderly)</ph>; <ph outputclass=\"caution\">history of hypertension (increased risk of proteinuria&#8212;discontinue if nephrotic syndrome)</ph>; <ph outputclass=\"caution\">increased risk of fistulas (discontinue permanently if tracheo-oesophageal or grade 4 fistula develops)</ph>; <ph outputclass=\"caution\">increased risk of haemorrhage</ph>; <ph outputclass=\"caution\">increased risk of tumour-associated haemorrhage</ph>; <ph outputclass=\"caution\">intra-abdominal inflammation (risk of gastro-intestinal perforation and gall bladder perforation</ph>; <ph outputclass=\"caution\">uncontrolled hypertension</ph>; <ph outputclass=\"caution\">untreated CNS metastases</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45447\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/bevacizumab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (bevacizumab).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45408\" outputclass=\"sideEffects\" rev=\"1.16\" parent=\"/drugs/bevacizumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">alopecia</ph>; <ph outputclass=\"sideEffect\">anaemia</ph>; <ph outputclass=\"sideEffect\">anorexia</ph>; <ph outputclass=\"sideEffect\">arterial thromboembolism</ph>; <ph outputclass=\"sideEffect\">asthenia</ph>; <ph outputclass=\"sideEffect\">bone marrow suppression</ph>; <ph outputclass=\"sideEffect\">chest pain</ph>; <ph outputclass=\"sideEffect\">congestive heart failure</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">dehydration</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dry skin</ph>; <ph outputclass=\"sideEffect\">dysarthria</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">exfoliative dermatitis</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">eye disorders</ph>; <ph outputclass=\"sideEffect\">fistulas</ph>; <ph outputclass=\"sideEffect\">flushing</ph>; <ph outputclass=\"sideEffect\">gall bladder perforation</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal perforation</ph>; <ph outputclass=\"sideEffect\">haemorrhage</ph>; <ph outputclass=\"sideEffect\">hand-foot syndrome</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">hypoxia</ph>; <ph outputclass=\"sideEffect\">impaired wound healing</ph>; <ph outputclass=\"sideEffect\">infection</ph>; <ph outputclass=\"sideEffect\">intestinal obstruction</ph>; <ph outputclass=\"sideEffect\">lethargy</ph>; <ph outputclass=\"sideEffect\">mucocutaneous bleeding</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">necrotising fasciitis (discontinue and initiate treatment promptly)</ph>; <ph outputclass=\"sideEffect\">neutropenia</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">osteonecrosis of the jaw</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">posterior reversible encephalopathy syndrome</ph>; <ph outputclass=\"sideEffect\">proteinuria</ph>; <ph outputclass=\"sideEffect\">pulmonary hypertension</ph>; <ph outputclass=\"sideEffect\">pyrexia</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">rhinitis</ph>; <ph outputclass=\"sideEffect\">rigors</ph>; <ph outputclass=\"sideEffect\">skin discoloration</ph>; <ph outputclass=\"sideEffect\">supraventricular tachycardia</ph>; <ph outputclass=\"sideEffect\">syncope</ph>; <ph outputclass=\"sideEffect\">taste disturbances</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45520\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/bevacizumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to before cytotoxic therapy begins&#8212;effective contraception required during and for at least 6 months after treatment in women.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45440\" outputclass=\"pregnancy\" parent=\"/drugs/bevacizumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45533\" outputclass=\"breastFeeding\" parent=\"/drugs/bevacizumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid breast-feeding during and for at least 6 months after treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45395\" outputclass=\"monitoringRequirements\" parent=\"/drugs/bevacizumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor for necrotising fasciitis (usually secondary to wound healing complications, gastro-intestinal perforation or fistula formation)&#8212;discontinue and initiate treatment promptly.</p>\n<p>Monitor blood pressure.</p>\n<p>Monitor for congestive heart failure.</p>\n<p>Monitor for posterior reversible encephalopathy syndrome (presenting as seizures, headache, altered mental status, visual disturbance or cortical blindness, with or without hypertension).</p>\n<p>Consider dental check-up before initiating treatment (risk of osteonecrosis of the jaw).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45380\" outputclass=\"nationalFunding\" rev=\"1.58\" parent=\"/drugs/bevacizumab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA118</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007)</p>\r\n<p>Bevacizumab in combination with fluorouracil plus folinic acid, with or without irinotecan, is <b>not</b> recommended for the first-line treatment of metastatic colorectal cancer; see also NICE guidance Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA118\">www.nice.org.uk/TA118</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA178</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Bevacizumab (first-line), sorafenib (firstand second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) </p>\r\n<p>Bevacizumab, sorafenib, and temsirolimus are <b>not</b> recommended as first-line treatments for people with advanced or metastatic renal cell carcinoma. Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA178\">www.nice.org.uk/TA178</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA212</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)</p>\r\n<p>Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is <b>not</b> recommended for the treatment of metastatic colorectal cancer.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA212\">www.nice.org.uk/TA212</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA214</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011)</p>\r\n<p>Bevacizumab in combination with a taxane is <b>not</b> recommended for the first-line treatment of metastatic breast cancer.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA214\">www.nice.org.uk/TA214</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA242</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012)</p>\r\n<p>Bevacizumab in combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy is <b>not</b> recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy; see also NICE guidance Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007).</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA242\">www.nice.org.uk/TA242</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA263</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012)</p>\r\n<p>Bevacizumab in combinations with capecitabine is <b>not</b> recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA263\">www.nice.org.uk/TA263</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA284</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer (May 2013)</p>\r\n<p>Bevacizumab in combination with paclitaxel and carboplatin is <b>not</b> recommended for the first-line treatment of advanced ovarian cancer (including fallopian tube and primary peritoneal cancer).</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA284\">www.nice.org.uk/TA284</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA285</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Bevacizumab in combination with gemcitabine and carboplatin for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (May 2013)</p>\r\n<p>Bevacizumab in combination with gemcitabine and carboplatin is <b>not</b> recommended within its marketing authorisation, that is, for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org/TA285\">www.nice.org/TA285</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (April 2012) that bevacizumab (<i>Avastin</i>\r\n<tm tmtype=\"reg\"/>) is <b>not</b> recommended for use within NHS Scotland for the first line treatment of patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5436-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/bevacizumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: solution for injection</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75890\" title=\"Solution for infusion\" namespace=\"/drugs/bevacizumab/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP97237\" namespace=\"/guidance/adverse-reactions-to-drugs\" title=\"Adverse reactions to drugs\" count=\"1\" rel=\"backlink\">Adverse reactions to drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1261\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/bevacizumab\" title=\"Bevacizumab\" count=\"1\" rel=\"link\">Bevacizumab</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75890\" namespace=\"/drugs/bevacizumab/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5436",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/bevacizumab",
    "basename": "bevacizumab",
    "title": "BEVACIZUMAB",
    "interactants": [
        {
            "id": "bnf_int_1261",
            "label": "Bevacizumab"
        }
    ],
    "vtmid": "409405006",
    "drugClassification": [
        "Monoclonal antibodies (antineoplastic)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor.",
                "html": "<p>\n<b>Bevacizumab</b> is a monoclonal antibody that inhibits vascular endothelial growth factor.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy",
                        "html": "Treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy"
                    },
                    {
                        "textContent": "First-line treatment of metastatic breast cancer in combination with paclitaxel when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate",
                        "html": "First-line treatment of metastatic breast cancer in combination with paclitaxel when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate"
                    },
                    {
                        "textContent": "First-line treatment of metastatic breast cancer in combination with capecitabine when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate (patients who have received adjuvant taxane or anthracycline-containing regimens in the previous 12 months should not be treated with bevacizumab in combination with capecitabine)",
                        "html": "First-line treatment of metastatic breast cancer in combination with capecitabine when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate (patients who have received adjuvant taxane or anthracycline-containing regimens in the previous 12 months should not be treated with bevacizumab in combination with capecitabine)"
                    },
                    {
                        "textContent": "Advanced or metastatic renal cell carcinoma in combination with interferon alfa-2a",
                        "html": "Advanced or metastatic renal cell carcinoma in combination with interferon alfa-2a"
                    },
                    {
                        "textContent": "First-line treatment of unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology (In combination with platinum-based chemotherapy)",
                        "html": "First-line treatment of unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology (In combination with platinum-based chemotherapy)"
                    },
                    {
                        "textContent": "First-line treatment of advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with carboplatin and paclitaxel)",
                        "html": "First-line treatment of advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with carboplatin and paclitaxel)"
                    },
                    {
                        "textContent": "First recurrence of platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have not been treated previously with bevacizumab or other drugs that target vascular endothelial growth factor (in combination with carboplatin and gemcitabine)",
                        "html": "First recurrence of platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have not been treated previously with bevacizumab or other drugs that target vascular endothelial growth factor (in combination with carboplatin and gemcitabine)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult local protocol).",
                        "html": "<p>(consult local protocol).</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "MHRA/CHM advice: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (January 2011)",
                "textContent": "Treatment with bevacizumab or sunitinib may be a risk factor for the development of osteonecrosis of the jaw.\n\nPatients treated with bevacizumab or sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.\n\nDental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.\n\nIf possible, invasive dental procedures should be avoided in patients treated with bevacizumab or sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.",
                "html": "<p>Treatment with bevacizumab or sunitinib may be a risk factor for the development of osteonecrosis of the jaw.</p><p>Patients treated with bevacizumab or sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.</p><p>Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.</p><p>If possible, invasive dental procedures should be avoided in patients treated with bevacizumab or sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.</p>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Elective surgery (withhold treatment and avoid for at least 28 days after major surgery or until wound fully healed)",
                "html": "Elective surgery (withhold treatment and avoid for at least 28 days after major surgery or until wound fully healed)"
            },
            {
                "type": "cautions",
                "textContent": "history of arterial thromboembolism",
                "html": "history of arterial thromboembolism"
            },
            {
                "type": "cautions",
                "textContent": "history of cardiovascular disease (increased risk of cardiovascular events, especially in the elderly)",
                "html": "history of cardiovascular disease (increased risk of cardiovascular events, especially in the elderly)"
            },
            {
                "type": "cautions",
                "textContent": "history of hypertension (increased risk of proteinuria&#8212;discontinue if nephrotic syndrome)",
                "html": "history of hypertension (increased risk of proteinuria&#8212;discontinue if nephrotic syndrome)"
            },
            {
                "type": "cautions",
                "textContent": "increased risk of fistulas (discontinue permanently if tracheo-oesophageal or grade 4 fistula develops)",
                "html": "increased risk of fistulas (discontinue permanently if tracheo-oesophageal or grade 4 fistula develops)"
            },
            {
                "type": "cautions",
                "textContent": "increased risk of haemorrhage",
                "html": "increased risk of haemorrhage"
            },
            {
                "type": "cautions",
                "textContent": "increased risk of tumour-associated haemorrhage",
                "html": "increased risk of tumour-associated haemorrhage"
            },
            {
                "type": "cautions",
                "textContent": "intra-abdominal inflammation (risk of gastro-intestinal perforation and gall bladder perforation",
                "html": "intra-abdominal inflammation (risk of gastro-intestinal perforation and gall bladder perforation"
            },
            {
                "type": "cautions",
                "textContent": "uncontrolled hypertension",
                "html": "uncontrolled hypertension"
            },
            {
                "type": "cautions",
                "textContent": "untreated CNS metastases",
                "html": "untreated CNS metastases"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (bevacizumab).",
                "html": "<p>Appendix 1 (bevacizumab).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "alopecia",
                        "html": "alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "anaemia",
                        "html": "anaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "anorexia",
                        "html": "anorexia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "arterial thromboembolism",
                        "html": "arterial thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "asthenia",
                        "html": "asthenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone marrow suppression",
                        "html": "bone marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "chest pain",
                        "html": "chest pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "congestive heart failure",
                        "html": "congestive heart failure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dehydration",
                        "html": "dehydration",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dry skin",
                        "html": "dry skin",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dysarthria",
                        "html": "dysarthria",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "exfoliative dermatitis",
                        "html": "exfoliative dermatitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "eye disorders",
                        "html": "eye disorders",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fistulas",
                        "html": "fistulas",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "flushing",
                        "html": "flushing",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gall bladder perforation",
                        "html": "gall bladder perforation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gastro-intestinal perforation",
                        "html": "gastro-intestinal perforation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "haemorrhage",
                        "html": "haemorrhage",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hand-foot syndrome",
                        "html": "hand-foot syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypoxia",
                        "html": "hypoxia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "impaired wound healing",
                        "html": "impaired wound healing",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "infection",
                        "html": "infection",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "intestinal obstruction",
                        "html": "intestinal obstruction",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "lethargy",
                        "html": "lethargy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "mucocutaneous bleeding",
                        "html": "mucocutaneous bleeding",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "necrotising fasciitis (discontinue and initiate treatment promptly)",
                        "html": "necrotising fasciitis (discontinue and initiate treatment promptly)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "neutropenia",
                        "html": "neutropenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "osteonecrosis of the jaw",
                        "html": "osteonecrosis of the jaw",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "posterior reversible encephalopathy syndrome",
                        "html": "posterior reversible encephalopathy syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "proteinuria",
                        "html": "proteinuria",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pulmonary hypertension",
                        "html": "pulmonary hypertension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pyrexia",
                        "html": "pyrexia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rhinitis",
                        "html": "rhinitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rigors",
                        "html": "rigors",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "skin discoloration",
                        "html": "skin discoloration",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "supraventricular tachycardia",
                        "html": "supraventricular tachycardia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "syncope",
                        "html": "syncope",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "taste disturbances",
                        "html": "taste disturbances",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to before cytotoxic therapy begins&#8212;effective contraception required during and for at least 6 months after treatment in women.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to before cytotoxic therapy begins&#8212;effective contraception required during and for at least 6 months after treatment in women.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;toxicity in animal studies.\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid&#8212;toxicity in <i>animal</i> studies.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid breast-feeding during and for at least 6 months after treatment.",
                "html": "<p>Manufacturer advises avoid breast-feeding during and for at least 6 months after treatment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor for necrotising fasciitis (usually secondary to wound healing complications, gastro-intestinal perforation or fistula formation)&#8212;discontinue and initiate treatment promptly.\n\nMonitor blood pressure.\n\nMonitor for congestive heart failure.\n\nMonitor for posterior reversible encephalopathy syndrome (presenting as seizures, headache, altered mental status, visual disturbance or cortical blindness, with or without hypertension).\n\nConsider dental check-up before initiating treatment (risk of osteonecrosis of the jaw).",
                "html": "<p>Monitor for necrotising fasciitis (usually secondary to wound healing complications, gastro-intestinal perforation or fistula formation)&#8212;discontinue and initiate treatment promptly.</p><p>Monitor blood pressure.</p><p>Monitor for congestive heart failure.</p><p>Monitor for posterior reversible encephalopathy syndrome (presenting as seizures, headache, altered mental status, visual disturbance or cortical blindness, with or without hypertension).</p><p>Consider dental check-up before initiating treatment (risk of osteonecrosis of the jaw).</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA118",
                        "label": "www.nice.org.uk/TA118"
                    }
                ],
                "fundingIdentifier": "NICE TA118",
                "textContent": "Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007) Bevacizumab in combination with fluorouracil plus folinic acid, with or without irinotecan, is not recommended for the first-line treatment of metastatic colorectal cancer; see also NICE guidance Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy.\n\nwww.nice.org.uk/TA118",
                "html": "<p outputclass=\"title\">Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007)</p> <p>Bevacizumab in combination with fluorouracil plus folinic acid, with or without irinotecan, is <b>not</b> recommended for the first-line treatment of metastatic colorectal cancer; see also NICE guidance Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA118\">www.nice.org.uk/TA118</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA178",
                        "label": "www.nice.org.uk/TA178"
                    }
                ],
                "fundingIdentifier": "NICE TA178",
                "textContent": "Bevacizumab (first-line), sorafenib (firstand second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) Bevacizumab, sorafenib, and temsirolimus are not recommended as first-line treatments for people with advanced or metastatic renal cell carcinoma. Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.\n\nwww.nice.org.uk/TA178",
                "html": "<p outputclass=\"title\">Bevacizumab (first-line), sorafenib (firstand second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) </p> <p>Bevacizumab, sorafenib, and temsirolimus are <b>not</b> recommended as first-line treatments for people with advanced or metastatic renal cell carcinoma. Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA178\">www.nice.org.uk/TA178</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA212",
                        "label": "www.nice.org.uk/TA212"
                    }
                ],
                "fundingIdentifier": "NICE TA212",
                "textContent": "Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010) Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is not recommended for the treatment of metastatic colorectal cancer.\n\nwww.nice.org.uk/TA212",
                "html": "<p outputclass=\"title\">Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)</p> <p>Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is <b>not</b> recommended for the treatment of metastatic colorectal cancer.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA212\">www.nice.org.uk/TA212</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA214",
                        "label": "www.nice.org.uk/TA214"
                    }
                ],
                "fundingIdentifier": "NICE TA214",
                "textContent": "Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011) Bevacizumab in combination with a taxane is not recommended for the first-line treatment of metastatic breast cancer.\n\nwww.nice.org.uk/TA214",
                "html": "<p outputclass=\"title\">Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011)</p> <p>Bevacizumab in combination with a taxane is <b>not</b> recommended for the first-line treatment of metastatic breast cancer.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA214\">www.nice.org.uk/TA214</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA242",
                        "label": "www.nice.org.uk/TA242"
                    }
                ],
                "fundingIdentifier": "NICE TA242",
                "textContent": "Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012) Bevacizumab in combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy is not recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy; see also NICE guidance Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007).\n\nwww.nice.org.uk/TA242",
                "html": "<p outputclass=\"title\">Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012)</p> <p>Bevacizumab in combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy is <b>not</b> recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy; see also NICE guidance Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007).</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA242\">www.nice.org.uk/TA242</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA263",
                        "label": "www.nice.org.uk/TA263"
                    }
                ],
                "fundingIdentifier": "NICE TA263",
                "textContent": "Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012) Bevacizumab in combinations with capecitabine is not recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months.\n\nwww.nice.org.uk/TA263",
                "html": "<p outputclass=\"title\">Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012)</p> <p>Bevacizumab in combinations with capecitabine is <b>not</b> recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA263\">www.nice.org.uk/TA263</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA284",
                        "label": "www.nice.org.uk/TA284"
                    }
                ],
                "fundingIdentifier": "NICE TA284",
                "textContent": "Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer (May 2013) Bevacizumab in combination with paclitaxel and carboplatin is not recommended for the first-line treatment of advanced ovarian cancer (including fallopian tube and primary peritoneal cancer).\n\nwww.nice.org.uk/TA284",
                "html": "<p outputclass=\"title\">Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer (May 2013)</p> <p>Bevacizumab in combination with paclitaxel and carboplatin is <b>not</b> recommended for the first-line treatment of advanced ovarian cancer (including fallopian tube and primary peritoneal cancer).</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA284\">www.nice.org.uk/TA284</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org/TA285",
                        "label": "www.nice.org/TA285"
                    }
                ],
                "fundingIdentifier": "NICE TA285",
                "textContent": "Bevacizumab in combination with gemcitabine and carboplatin for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (May 2013) Bevacizumab in combination with gemcitabine and carboplatin is not recommended within its marketing authorisation, that is, for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.\n\nwww.nice.org/TA285",
                "html": "<p outputclass=\"title\">Bevacizumab in combination with gemcitabine and carboplatin for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (May 2013)</p> <p>Bevacizumab in combination with gemcitabine and carboplatin is <b>not</b> recommended within its marketing authorisation, that is, for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.</p><xref format=\"html\" href=\"http://www.nice.org/TA285\">www.nice.org/TA285</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "solution for injection"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75890",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP97237",
                "label": "Adverse reactions to drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1261",
                "label": "Bevacizumab",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75890",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}